Abstracts tagged "SLE and belimumab"

Abstract Number: 1086 • 2016 ACR/ARHP Annual Meeting
Analysis of the Naive B Cell Repertoire in Belimumab Treated SLE Patients
Weiqing Huang¹, Cynthia Aranow², Cosmin Dascalu¹, Richard Furie³ and Anne Davidson⁴, ¹Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY
Background/Purpose: BAFF is a TNF-like cytokine that supports the survival and differentiation of B cells. The anti-BAFF antibody belimumab is the only new drug that…
Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting
Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Herbert Struemper¹, William Freimuth², Christi Kleoudis³, Thi-Sau Migone⁴, David Roth³ and William Stohl⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Human Genome Sciences, Inc., Rockville, MD, ³GlaxoSmithKline, King of Prussia, PA, ⁴Igenica, Burlingame, CA, ⁵Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…
Abstract Number: 1574 • 2013 ACR/ARHP Annual Meeting
Favorable Clinical Response To Belimumab At Three Months
Anca Askanase¹, Arthi Reddy¹, Jill P. Buyon², Andrew G. Franks Jr.³, Richard A. Furie⁴, Diane L. Kamen⁵, Susan Manzi⁶, Michelle Petri⁷, Rosalind Ramsey-Goldman⁸, Chung-E Tseng⁹, Ronald F. van Vollenhoven¹⁰ and Daniel J. Wallace¹¹, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Dermatology & Medicine (Rheumatology), New York University, New York, NY, ⁴The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹NYU School of Medicine, New York, NY, ¹⁰Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the…